Pub Date : 2018-01-01DOI: 10.4172/2329-6771.1000213
Fasil Sisay, Sofia Kebede, A. Abebe, Fikrte woldeselassie, Girum Sebsibie, Teklemariam Gultie
{"title":"Treatment Outcome of Oncologic Patients Treated in the Emergency Department at Black Lion Specialized Hospital, Ethiopia","authors":"Fasil Sisay, Sofia Kebede, A. Abebe, Fikrte woldeselassie, Girum Sebsibie, Teklemariam Gultie","doi":"10.4172/2329-6771.1000213","DOIUrl":"https://doi.org/10.4172/2329-6771.1000213","url":null,"abstract":"","PeriodicalId":16252,"journal":{"name":"Journal of Integrative Oncology","volume":"42 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78195565","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-01-01DOI: 10.4172/2329-6771.1000203
A. Ng, G. Francis, Sumler Ss, Diane D. Liu, E. Bruera
Background: Cancer patients have a 4 to 7 fold increase in the frequency of Venous Thromboembolism (VTE) during treatment and VTE is a common cause of death. Oncology massage has been traditionally contraindicated in patients with thromboembolism, but studies show oncology massage improves symptoms and quality of life.Objectives: The purpose of this study was to review the safety and patient reported outcomes of massage in oncologic patients with a recent history of VTE.Methods: After obtaining UT MD Anderson institutional review board approval, 25 patients who received oncology massage for symptom relief and quality of life, following the diagnosis of VTE were retrospectively reviewed. Edmonton Symptom Assessment Scale (ESAS) scores were reviewed pre- and post-massage, as well as complications within 30 days requiring return to the Emergency Room or hospital re-admission.Results: 19 patients with complete ESAS scores reported a significant improvement in pain, fatigue, anxiety and well-being. Eleven patients (44%) returned to the emergency department within 30 days of their most recent massage, due to disease progression, fatigue and diarrhea. None of the 25 patients had complications due to massage. One patient experienced a new VTE 7 days after finishing massage, (patient was off anti-coagulation secondary to a pseudoaneurysm bleed).Conclusions: Our study suggests that if precautions are taken not to massage the anatomic site of the VTE, patients are afebrile and have >50,000 platelets with no coagulopathy, oncologic massage is a safe, non-invasive intervention even following VTE for improvement in generalized pain, fatigue and quality of life.
{"title":"The Efficacy and Safety of Massage Therapy for Cancer Inpatients with Venous Thromboembolism","authors":"A. Ng, G. Francis, Sumler Ss, Diane D. Liu, E. Bruera","doi":"10.4172/2329-6771.1000203","DOIUrl":"https://doi.org/10.4172/2329-6771.1000203","url":null,"abstract":"Background: Cancer patients have a 4 to 7 fold increase in the frequency of Venous Thromboembolism (VTE) during treatment and VTE is a common cause of death. Oncology massage has been traditionally contraindicated in patients with thromboembolism, but studies show oncology massage improves symptoms and quality of life.Objectives: The purpose of this study was to review the safety and patient reported outcomes of massage in oncologic patients with a recent history of VTE.Methods: After obtaining UT MD Anderson institutional review board approval, 25 patients who received oncology massage for symptom relief and quality of life, following the diagnosis of VTE were retrospectively reviewed. Edmonton Symptom Assessment Scale (ESAS) scores were reviewed pre- and post-massage, as well as complications within 30 days requiring return to the Emergency Room or hospital re-admission.Results: 19 patients with complete ESAS scores reported a significant improvement in pain, fatigue, anxiety and well-being. Eleven patients (44%) returned to the emergency department within 30 days of their most recent massage, due to disease progression, fatigue and diarrhea. None of the 25 patients had complications due to massage. One patient experienced a new VTE 7 days after finishing massage, (patient was off anti-coagulation secondary to a pseudoaneurysm bleed).Conclusions: Our study suggests that if precautions are taken not to massage the anatomic site of the VTE, patients are afebrile and have >50,000 platelets with no coagulopathy, oncologic massage is a safe, non-invasive intervention even following VTE for improvement in generalized pain, fatigue and quality of life.","PeriodicalId":16252,"journal":{"name":"Journal of Integrative Oncology","volume":"75 1","pages":"1-5"},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86166086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-01-01DOI: 10.4172/2329-6771.1000216
Shagufta Shaheen, S. Otoukesh, B. Jabo, Manmeet Kaur, Nicole D Wheeler, S. Mirshahidi, S. Zaheer, H. Mirshahidi
Lung cancer is the leading cause of cancer-related mortalities around the world [1]. Potentially curable early stage Non-Small-Cell Lung Cancer (NSCLC) can be found in one-third of this patient population [2]. Surgical resection remains the backbone of treatment in resectable lung cancers. The introduction of VATS in 1994 [3] sparked interest in minimally invasive tumor resection. VATS has also been shown to have fewer postoperative complications [4] and has been associated with decreased postoperative pain and increased quality of life compared to OT [5]. Several studies have compared these two approaches indirectly, but no randomized controlled trial has investigated the long-term effect on outcomes. We aim to investigate the long-term Disease-Free Survival (DFS) and OS of patients with lung cancer undergoing lung resection by OT or VATS for resectable stage lung cancer. Patients and Methods
{"title":"Less is More: Video-Assisted Thoracic Surgery (VATS) vs. Open Thoracotomy (OT) in the Management of Resectable Lung Cancer","authors":"Shagufta Shaheen, S. Otoukesh, B. Jabo, Manmeet Kaur, Nicole D Wheeler, S. Mirshahidi, S. Zaheer, H. Mirshahidi","doi":"10.4172/2329-6771.1000216","DOIUrl":"https://doi.org/10.4172/2329-6771.1000216","url":null,"abstract":"Lung cancer is the leading cause of cancer-related mortalities around the world [1]. Potentially curable early stage Non-Small-Cell Lung Cancer (NSCLC) can be found in one-third of this patient population [2]. Surgical resection remains the backbone of treatment in resectable lung cancers. The introduction of VATS in 1994 [3] sparked interest in minimally invasive tumor resection. VATS has also been shown to have fewer postoperative complications [4] and has been associated with decreased postoperative pain and increased quality of life compared to OT [5]. Several studies have compared these two approaches indirectly, but no randomized controlled trial has investigated the long-term effect on outcomes. We aim to investigate the long-term Disease-Free Survival (DFS) and OS of patients with lung cancer undergoing lung resection by OT or VATS for resectable stage lung cancer. Patients and Methods","PeriodicalId":16252,"journal":{"name":"Journal of Integrative Oncology","volume":"9 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83198866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-01-01DOI: 10.4172/2329-6771.1000217
Anu Bajaj
A frequent form of adult leukemia may be manifest by an accretion of functionally incompetent lymphocytes gradually within the peripheral blood, bone marrow, spleen and lymph nodes which may be designated as a CLL. An annual estimation of 1500 instances may be elucidated with CLL in the developed world. The disease may be detected coincidentally at a median age of 72 years or may clinically manifest with a coexistent tumor encumbrance, autoimmune disorders or infections. An ALC of mature-appearing lymphocytes greater than 5000 cells/μL with an immune reactivity to CD5+, CD19+, CD23+, and a kappa/lambda light chain restriction of the surface immunoglobulin may be delineated. The disorder may be labeled as SLL in situations where the ALC persists below 5000 cells/μL [1]. SLL frequently arises in the middle-aged or elderly individuals and generally elucidates a favorable outcome. It may be discovered coincidentally in lymph nodes examined for suspected carcinomas. The condition may usually be discovered at a median age of 72 years. An estimated 10% of the implicated individuals may be first degree relatives of CLL patients or below 50 years of age [1]. The disease demonstrates a male predominance with a male to female ratio (M:F) of 2:1. The environmental factors engendering the lymphocytic transformation may be indeterminate, though the exposure to agent orange in specific war veterans may be considered [1].
{"title":"Monotonous and Massive: Small Lymphocytic Lymphoma","authors":"Anu Bajaj","doi":"10.4172/2329-6771.1000217","DOIUrl":"https://doi.org/10.4172/2329-6771.1000217","url":null,"abstract":"A frequent form of adult leukemia may be manifest by an accretion of functionally incompetent lymphocytes gradually within the peripheral blood, bone marrow, spleen and lymph nodes which may be designated as a CLL. An annual estimation of 1500 instances may be elucidated with CLL in the developed world. The disease may be detected coincidentally at a median age of 72 years or may clinically manifest with a coexistent tumor encumbrance, autoimmune disorders or infections. An ALC of mature-appearing lymphocytes greater than 5000 cells/μL with an immune reactivity to CD5+, CD19+, CD23+, and a kappa/lambda light chain restriction of the surface immunoglobulin may be delineated. The disorder may be labeled as SLL in situations where the ALC persists below 5000 cells/μL [1]. SLL frequently arises in the middle-aged or elderly individuals and generally elucidates a favorable outcome. It may be discovered coincidentally in lymph nodes examined for suspected carcinomas. The condition may usually be discovered at a median age of 72 years. An estimated 10% of the implicated individuals may be first degree relatives of CLL patients or below 50 years of age [1]. The disease demonstrates a male predominance with a male to female ratio (M:F) of 2:1. The environmental factors engendering the lymphocytic transformation may be indeterminate, though the exposure to agent orange in specific war veterans may be considered [1].","PeriodicalId":16252,"journal":{"name":"Journal of Integrative Oncology","volume":"16 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81973829","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-01-01DOI: 10.4172/2329-6771.1000219
Ketan Bhatikar
Mastectomy is a treatment for breast cancer over breast-conserving surgeries. There are many side effects known post-mastectomy. Some of which are pain tenderness, swelling at the surgery site, lymphadenopathy, buildup of blood in the wound (hematoma), the buildup of clear fluid in the wound (seroma), limited arm or shoulder movement, numbness in the chest or upper arm, neuropathic pain [1]. Mastectomy also caused the psychological impact on half of the patients, which included fear of cancer, feeling of body incompleteness, inconvenience in working and social communication, less sexual act and low spirit [2]. Lymphedema in women treated for breast cancer is an accumulation of protein-rich fluid in the arm that occurs when axillary lymphatic drainage from the arm is interrupted because of axillary lymph node dissection or axillary radiation or both [3]. Lymphedema is still of great concern as no modern modalities have shown significant results in reducing lymphedema. This leads to dysfunction in the shoulder joint and restriction in joint range. Three stages of lymphedema have been described in studies that are: Stage I presents with pitting and is considered reversible; some women with this stage have no increased arm girth or heaviness and no signs of pitting edema. As the edema progresses, it becomes brawny, fibrotic, nonpitting and irreversible in stage II. In advanced lymphedema i.e. in stage III, which rarely occurs following breast cancer treatments, cartilaginous hardening occurs, with papillomatous outgrowths and hyperkeratosis of the skin [4-6]. Chronic lymphedema gives rise to a chronic inflammatory state and consequent fibrosis that make the joint range more difficult to treat with pain [7]. This further leads to symptoms such as pain, disfigurement, and disability.
{"title":"Evaluation of Long-Term Effect of Clinical Physiotherapy Treatment Protocol for Post Cancer Mastectomy Induced Lymphadenopathy and Restricted Joint Range: A Novel Protocol Case Study","authors":"Ketan Bhatikar","doi":"10.4172/2329-6771.1000219","DOIUrl":"https://doi.org/10.4172/2329-6771.1000219","url":null,"abstract":"Mastectomy is a treatment for breast cancer over breast-conserving surgeries. There are many side effects known post-mastectomy. Some of which are pain tenderness, swelling at the surgery site, lymphadenopathy, buildup of blood in the wound (hematoma), the buildup of clear fluid in the wound (seroma), limited arm or shoulder movement, numbness in the chest or upper arm, neuropathic pain [1]. Mastectomy also caused the psychological impact on half of the patients, which included fear of cancer, feeling of body incompleteness, inconvenience in working and social communication, less sexual act and low spirit [2]. Lymphedema in women treated for breast cancer is an accumulation of protein-rich fluid in the arm that occurs when axillary lymphatic drainage from the arm is interrupted because of axillary lymph node dissection or axillary radiation or both [3]. Lymphedema is still of great concern as no modern modalities have shown significant results in reducing lymphedema. This leads to dysfunction in the shoulder joint and restriction in joint range. Three stages of lymphedema have been described in studies that are: Stage I presents with pitting and is considered reversible; some women with this stage have no increased arm girth or heaviness and no signs of pitting edema. As the edema progresses, it becomes brawny, fibrotic, nonpitting and irreversible in stage II. In advanced lymphedema i.e. in stage III, which rarely occurs following breast cancer treatments, cartilaginous hardening occurs, with papillomatous outgrowths and hyperkeratosis of the skin [4-6]. Chronic lymphedema gives rise to a chronic inflammatory state and consequent fibrosis that make the joint range more difficult to treat with pain [7]. This further leads to symptoms such as pain, disfigurement, and disability.","PeriodicalId":16252,"journal":{"name":"Journal of Integrative Oncology","volume":"37 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84030106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-01-01DOI: 10.4172/2329-6771.1000211
Berrin Inanc, Kubilay Inanc, B. Yucel
Radiotherapy treatment for cervical cancer may cause secondary cancer within both surrounding organs and those farthest away. Here we report a case report of kidney cancer developed after curative radiotherapy treatment for cervical cancer which was detected with Computerized Tomography (CT) five years later.
{"title":"A Case Report: Radiation-Induced Kidney Cancer after Treatment for Cervical Cancer","authors":"Berrin Inanc, Kubilay Inanc, B. Yucel","doi":"10.4172/2329-6771.1000211","DOIUrl":"https://doi.org/10.4172/2329-6771.1000211","url":null,"abstract":"Radiotherapy treatment for cervical cancer may cause secondary cancer within both surrounding organs and those farthest away. Here we report a case report of kidney cancer developed after curative radiotherapy treatment for cervical cancer which was detected with Computerized Tomography (CT) five years later.","PeriodicalId":16252,"journal":{"name":"Journal of Integrative Oncology","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89329367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-01-01DOI: 10.4172/2329-6771.1000204
A. Purkayastha, Sankalp Singh, N. Bisht, D. Shelly, R. Bharadwaj, H. Singh, A. Kapoor, Deepak Mulajkar, Sameer Gupta, Richa Joshi
Invasive or infiltrating ductal carcinoma is the most common type of breast cancer while primary squamous cell carcinoma of breast is extremely rare occurring in 0.04%-0.1% of all breast cancer cases known for aggressive behaviour and poor prognosis. We hereby report a case of primary squamous cell carcinoma of breast in a 31-yearold female who presented with a left breast lump of 2 months duration. Lumpectomy done at another non-oncology centre showed invasive ductal carcinoma with margin positivity for which she underwent modified radical mastectomy at our institute. Post-operative immune-histopathology revealed triple negative squamous cell carcinoma. Her metastatic work-up with whole-body positron emission tomography scan was negative. She was treated with adjuvant chemotherapy doxorubicin, cyclophosphamide and docetaxel followed by loco-regional radiotherapy to left chest wall which she tolerated well. No hormonal therapy was given in view of hormone receptor negativity. She is presently on follow-up for more than 6 months without any evidence of recurrence or distant metastasis. This case is being presented to highlight its extreme rarity, it’s occurrence in a young female, the diagnostic and therapeutic challenges it presented and the overall prognosis of this neoplasm.
{"title":"Primary Squamous Cell Carcinoma of Breast in a Young Female: An Institutional Experience with Review of Literature","authors":"A. Purkayastha, Sankalp Singh, N. Bisht, D. Shelly, R. Bharadwaj, H. Singh, A. Kapoor, Deepak Mulajkar, Sameer Gupta, Richa Joshi","doi":"10.4172/2329-6771.1000204","DOIUrl":"https://doi.org/10.4172/2329-6771.1000204","url":null,"abstract":"Invasive or infiltrating ductal carcinoma is the most common type of breast cancer while primary squamous cell carcinoma of breast is extremely rare occurring in 0.04%-0.1% of all breast cancer cases known for aggressive behaviour and poor prognosis. We hereby report a case of primary squamous cell carcinoma of breast in a 31-yearold female who presented with a left breast lump of 2 months duration. Lumpectomy done at another non-oncology centre showed invasive ductal carcinoma with margin positivity for which she underwent modified radical mastectomy at our institute. Post-operative immune-histopathology revealed triple negative squamous cell carcinoma. Her metastatic work-up with whole-body positron emission tomography scan was negative. She was treated with adjuvant chemotherapy doxorubicin, cyclophosphamide and docetaxel followed by loco-regional radiotherapy to left chest wall which she tolerated well. No hormonal therapy was given in view of hormone receptor negativity. She is presently on follow-up for more than 6 months without any evidence of recurrence or distant metastasis. This case is being presented to highlight its extreme rarity, it’s occurrence in a young female, the diagnostic and therapeutic challenges it presented and the overall prognosis of this neoplasm.","PeriodicalId":16252,"journal":{"name":"Journal of Integrative Oncology","volume":"24 1","pages":"1-4"},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81135771","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-01-01DOI: 10.4172/2329-6771.1000210
B. Brevitt, Peter Johnson, M. Voutchkov
Objectives: To conduct a comparative analysis of ED delivered during CT examinations of the brain, chest and abdomen in three major Jamaican radiology centres.Methodology: Retrospective review of CT dose reports for patients referred for CT evaluation of the brain, chest and abdomen in 2016. 180 patients age 30 and under were targeted. This review was conducted with the guidance of a Radiologist.Results: There were variations of ED among facilities conducting CT examinations of similar anatomic areas ranging from 8.03 mSv to 23.2 mSv. In excess of 50% of the cases reviewed reported normal radiological findings.Conclusion: There is a need to manage and document ED delivered to patients during CT procedures as ED contributes to increased risk of cancers.
{"title":"Importance of Diagnostic Efficacy and Effective Dose Documentation Computed Tomography Procedures","authors":"B. Brevitt, Peter Johnson, M. Voutchkov","doi":"10.4172/2329-6771.1000210","DOIUrl":"https://doi.org/10.4172/2329-6771.1000210","url":null,"abstract":"Objectives: To conduct a comparative analysis of ED delivered during CT examinations of the brain, chest and abdomen in three major Jamaican radiology centres.Methodology: Retrospective review of CT dose reports for patients referred for CT evaluation of the brain, chest and abdomen in 2016. 180 patients age 30 and under were targeted. This review was conducted with the guidance of a Radiologist.Results: There were variations of ED among facilities conducting CT examinations of similar anatomic areas ranging from 8.03 mSv to 23.2 mSv. In excess of 50% of the cases reviewed reported normal radiological findings.Conclusion: There is a need to manage and document ED delivered to patients during CT procedures as ED contributes to increased risk of cancers.","PeriodicalId":16252,"journal":{"name":"Journal of Integrative Oncology","volume":"8 1","pages":"1-4"},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75367737","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-01-01DOI: 10.4172/2329-6771-C3-009
P. Sudhakar, G. Paddaiahp
{"title":"Nasolabial fold inflammatory myofibroblastic tumor (Rare presentation): Case report and literature review","authors":"P. Sudhakar, G. Paddaiahp","doi":"10.4172/2329-6771-C3-009","DOIUrl":"https://doi.org/10.4172/2329-6771-C3-009","url":null,"abstract":"","PeriodicalId":16252,"journal":{"name":"Journal of Integrative Oncology","volume":"50 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79377905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-01-01DOI: 10.4172/2329-6771.1000212
J. Castro, L. Sánchez, Pierino H Alvarez Bedoya, M. T. Núñez, Ming Lu, Tomas Castro, H. Sharifi, C. Ericsson
Cancer screening is an approach to reduce cancer-related morbidity and mortality rates. Among those screening tests that have been shown to lead to reduction in cancer deaths 2 tissue biomarkers, PSA and CA-125 have shown to contribute to clinical utility. No tumor marker has however been identified to date that is sufficiently sensitive or specific to be used on its own to screen for cancer. Screening for circulation tumor cells as a new biomarker in the blood therefore seems like an attractive possibility. Cancer is known to spread circulating tumor cells before symptoms occur. Therefore, we have screened 1,585 asymptomatic individuals of age 20 to 80 with no known cancer risk factors. 27 individuals showed one or more circulating tumor cell in a 7.5 ml blood sample, which constitutes a positive circulating tumor cell test, based on the iCellate IsoPicTM laboratory test. That number compares favourably with the cancer incidence of 157.1 per 100,000 people per year in Peru, given that the screening results would be expected to correspond to an accumulated incidence of up to 12 years. The present findings therefore identify circulating tumor cells as a promising new cancer screening test.
{"title":"Screening Circulating Tumor Cells as a Non-invasive Cancer Test in 1,585 Asymptomatic Adults (ICELLATE1)","authors":"J. Castro, L. Sánchez, Pierino H Alvarez Bedoya, M. T. Núñez, Ming Lu, Tomas Castro, H. Sharifi, C. Ericsson","doi":"10.4172/2329-6771.1000212","DOIUrl":"https://doi.org/10.4172/2329-6771.1000212","url":null,"abstract":"Cancer screening is an approach to reduce cancer-related morbidity and mortality rates. Among those screening tests that have been shown to lead to reduction in cancer deaths 2 tissue biomarkers, PSA and CA-125 have shown to contribute to clinical utility. No tumor marker has however been identified to date that is sufficiently sensitive or specific to be used on its own to screen for cancer. Screening for circulation tumor cells as a new biomarker in the blood therefore seems like an attractive possibility. Cancer is known to spread circulating tumor cells before symptoms occur. Therefore, we have screened 1,585 asymptomatic individuals of age 20 to 80 with no known cancer risk factors. 27 individuals showed one or more circulating tumor cell in a 7.5 ml blood sample, which constitutes a positive circulating tumor cell test, based on the iCellate IsoPicTM laboratory test. That number compares favourably with the cancer incidence of 157.1 per 100,000 people per year in Peru, given that the screening results would be expected to correspond to an accumulated incidence of up to 12 years. The present findings therefore identify circulating tumor cells as a promising new cancer screening test.","PeriodicalId":16252,"journal":{"name":"Journal of Integrative Oncology","volume":"53 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80398068","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：